BioCentury | Jun 8, 2015
Company News

Urigen, Imprimis deal

...Imprimis exercised its option to convert its non-exclusive, U.S. license to Urigen’s Hep-Lido-A to an exclusive...
BioCentury | May 3, 2010
Company News

Oceana, Urigen deal

...deal that gave Oceana a right of first refusal to license all indications of Urigen's URG101...
...was to assist Urigen in preparing for a Phase II meeting with the agency regarding URG101...
...ending the contractual obligation with Oceana would enable it to pursue other commercial partnerships for URG101...
BioCentury | Jan 4, 2010
Company News

Oceana, Urigen deal

...Urigen granted Oceana a right of first refusal to license all indications of URG101 that may...
...a Phase II meeting with FDA about the intravesical formulation of heparin and alkalinized lidocaine. URG101...
...said it was seeking strategic alternatives, including the license or formation of a JV around URG101...
BioCentury | May 4, 2009
Company News

Urigen genitourinary news

...strategic alternatives, including the license or formation of a JV around its URG101 and URG301. URG101...
BioCentury | Nov 10, 2008
Company News

Urigen genitourinary news

...The company is seeking product financing, partnerships and other strategic alternatives. Its lead compound is URG101...
BioCentury | Apr 14, 2008
Company News

Mattern Pharmaceuticals AG, Urigen deal

...to URG101 , which completed a Phase II trial early based on positive interim data. URG101...
BioCentury | Mar 17, 2008
Clinical News

URG101: Interim Phase II data

...URG101-104 trial in the first 21 completed patients showed that a single, intravesical administration of URG101...
...primary endpoint of superiority vs. placebo for improvement in Average Daytime Pain (p=0.03). Patients receiving URG101...
...both) and for symptom relief using PORIS (p=0.01). Urigen Pharmaceuticals Inc. (OTCBB:URGP), Burlingame, Calif. Product: URG101...
BioCentury | Dec 10, 2007
Company News

Hyaluron Inc., Urigen deal

...Hyaluron will manufacture URGP's URG101 for clinical studies. The intravesical formulation of heparin and alkalinized lidocaine...
...clinical studies. The intravesical formulation of heparin and alkalinized lidocaine is in the Phase II URG101-104...
BioCentury | Aug 20, 2007
Clinical News

URG101: Phase II started

...URGP began the double-blind, placebo-controlled, cross-over, U.S. Phase II URG101-104 trial in 40 patients with acute...
...patients with acute symptoms of painful bladder syndrome. Urigen Pharmaceuticals Inc. (URGP), Burlingame, Calif. Product: URG101...
BioCentury | Nov 6, 2006
Clinical News

U101: Phase IIb data

...Phase IIb trial in 90 patients with chronic pelvic pain of bladder origin showed that U101...
...merging with Valentis Inc. (VLTS, Burlingame, Calif.). Urigen NA Inc. , San Francisco, Calif. Product: U101...
Items per page:
1 - 10 of 13